Emergent BioSolutions Inc. today announced that it has initiated manufacturing of BioThraxA consistency lots in Building 55, following review by the U.S. Food and Drug Administration of the Manufacturing and Non-Clinical Study Protocols submitted by the company supporting the Building 55 comparability program.
http://ift.tt/1hbmB6g
http://ift.tt/1hbmB6g
No comments:
Post a Comment